ストックスクリーナーアプリを入手
2.28
16.92%
0.33
アフターアワーズ：
2.26
-0.02
-0.88%
前日終値:
$1.95
開ける：
$1.95
24時間の取引高:
12.71M
Relative Volume:
4.00
時価総額：
$188.27M
収益：
-
当期純損益:
$-314.85M
株価収益率:
-0.6364
EPS:
-3.5825
ネットキャッシュフロー:
$-283.27M
1週間 パフォーマンス:
-61.26%
1か月 パフォーマンス:
-68.07%
6か月 パフォーマンス:
-51.90%
1年 パフォーマンス:
-70.43%
1日の値動き範囲:
$1.92
$2.30
1週間の範囲:
$1.50
$6.65
52週間の値動き範囲:
$1.50
$13.24
Replimune Group Inc Stock (REPL) Company Profile
Compare REPL vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
2.28 | 161.02M | 0 | -314.85M | -283.27M | -3.5825 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-11-03 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | アップグレード | JP Morgan | Underweight → Neutral |
| 2025-10-20 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | アップグレード | Wedbush | Neutral → Outperform |
| 2025-09-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-07-30 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | ダウングレード | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-07-23 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-07-22 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | ダウングレード | Wedbush | Outperform → Neutral |
| 2025-06-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-28 | 開始されました | ROTH MKM | Buy |
| 2023-04-17 | 再開されました | Piper Sandler | Overweight |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2020-11-17 | 開始されました | BTIG Research | Buy |
| 2020-11-02 | 開始されました | Jefferies | Buy |
| 2020-10-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2019-09-04 | 開始されました | ROTH Capital | Buy |
| 2019-07-23 | 開始されました | Chardan Capital Markets | Buy |
| 2019-07-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-04-25 | 開始されました | Wedbush | Outperform |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 開始されました | JP Morgan | Overweight |
| 2018-08-14 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Replimune Group Inc (REPL) 最新ニュース
Why Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma Application And What's Next - simplywall.st
Mass. biotech company to lay off 63 employees after FDA rejects cancer drug for 2nd time - MassLive
Replimune Group FY2026 EPS Estimate Lifted by HC Wainwright - MarketBeat
J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer - BioSpace
Replimune Group, Inc. Cash Ratio | REPL - MLQ.ai
Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma BLA Over Trial Design Concerns - Yahoo Finance
REPL Slides After Insider Filings Spark Trader Caution - StocksToTrade
FDA Rejection Sparks Questions On Replimune Drug Approval Path - Sahm
Replimune plunges after FDA rejects skin cancer drug again - MSN
Jefferies downgrades Replimune Group (REPL) - MSN
Massachussetts Biotech Co. Faces Major Melanoma Drug Setback - Streetwise Reports
Wedbush downgrades Replimune Group (REPL) - MSN
MA Biotech Co. Downgraded to Sell After Second FDA CRL for RP-1 Melanoma BLA - Streetwise Reports
REPL Downgraded by JP Morgan -- Rating Changed to Underweight - GuruFocus
Recon: FDA denies Replimune’s cancer drug over trial issues; Revolution’s cancer pill boosts survival in Phase 3 trial - RAPS.org
Fastenal, Replimune Group, Children's Place and other big stocks moving lower in Monday's pre-market session - MSN
Replimune Plans Layoffs After FDA Rejects Cancer Therapy. The Stock Hits an All-Time Low. - Barron's
REPL Downgraded by Cantor Fitzgerald -- Rating Changed to Neutra - GuruFocus
Replimune plunges after second FDA setback for melanoma therapy; analysts turn bearish - MSN
REPL Downgraded by Wedbush -- Price Target Lowered to $2.00 - GuruFocus
REPL Downgraded by Leerink Partners -- Price Target Lowered to $2.00 - GuruFocus
Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%. -- Barrons.com - Moomoo
REPL Downgraded by Jefferies -- Price Target Lowered to $2.00 - GuruFocus
Replimune Receives FDA Complete Response Letter for RP1 Biologics License Application in Advanced Melanoma, Plans Major Cutbacks - Minichart
Replimune Group (REPL) Faces Downgrades After FDA Rejects Melano - GuruFocus
Replimune Shares Plummet to All-Time Low as FDA Rejection Muddies Path Forward - marketscreener.com
FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment - Pharmaceutical Executive
Replimune Receives Second CRL for RP1 With Nivolumab for Treatment of Advanced Melanoma - Pharmacy Times
Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes - Zacks Investment Research
Street sours on Replimune as stock hits all-time low on melanoma drug rejection - Seeking Alpha
Replimune’s RP1 setback deepens after second FDA rejection - The Pharma Letter
REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays - MSN
Cantor Fitzgerald Reaffirms Neutral Rating for Replimune Group (NASDAQ:REPL) - MarketBeat
Replimune Group REPL Plunges After FDA Melanoma Rejection - StocksToTrade
Biggest stock movers Monday: REPL, GS, LEG and more (NYSE:GS) - Seeking Alpha
Replimune Group (NASDAQ:REPL) Lowered to "Underperform" Rating by BMO Capital Markets - MarketBeat
REPL Downgraded by HC Wainwright & Co. -- Rating Changed to Sell - GuruFocus
Pharmalittle: We're reading about a pancreatic cancer pill, FDA rejecting a Replimune drug again, and more - statnews.com
This NXP Semiconductors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Replimune Group (NASDAQ:REPL) Earns "Market Perform" Rating from Leerink Partners - MarketBeat
Replimune Group (NASDAQ:REPL) Receives "Neutral" Rating from Wedbush - MarketBeat
Replimune Group's (REPL) "Hold" Rating Reiterated at Jefferies Financial Group - MarketBeat
JPMorgan Chase & Co. Reaffirms Underweight Rating for Replimune Group (NASDAQ:REPL) - MarketBeat
FDA issues complete response letter to Replimune’s RP1 for melanoma - Pharmaceutical Technology
Replimune Group (NASDAQ:REPL) Given Sell Rating at HC Wainwright - MarketBeat
Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Sess - Benzinga
US Premarket Movers: Baker Hughes, Goldman, Leggett, Replimune - Bloomberg.com
Replimune Group, Inc. Shareholders Are Encouraged to Reach - GlobeNewswire
Piper Sandler Downgrades Replimune to Neutral From Overweight, Adjusts Price Target to $4 From $14 - marketscreener.com
Replimune melanoma therapy rejected by FDA, shares plunge - Proactive financial news
BMO Capital Downgrades Replimune to Underperform From Market Perform, Adjusts PT to $1 From $11 - marketscreener.com
Replimune Group Inc (REPL) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):